Prostacyclins Within Treatment of Pediatric Pulmonary Hypertension
This activity will provide pharmacists, residents, and pharmacy technicians with information in order to help determine how to provide safe and efficacious therapy options for the pediatric patients with pulmonary hypertension. The most recent guidelines for pediatric pulmonary hypertension are recommendations from the American Heart Association and American Thoracic Society, but there have not been any updates since 2015. Traditionally, nitric oxide has been the gold standard of therapy. However, this is a costly inhalation therapy and provides potential complications to patients that require treatment therapy in the outpatient setting. With newer primary literature emerging, prostacyclins have been shown to be more cost effective compared to nitric oxide and have some newer studies demonstrating that it can be used as an alternative therapy or when refractory to nitric oxide therapy. This presentation will review primary literature behind the use of prostacyclin therapy for pediatric pulmonary hypertension and help identify its place in practice.
Target Audience
- Pharmacists
- Pharmacy technicians
Learning Objectives
Pharmacist learning objectives
- Review the current guidelines for pediatric pulmonary hypertension
- Discuss updates to literature since the published 2015 American Heart Association/American Thoracic Society guidelines for pediatric pulmonary hypertension
- Determine where prostacyclins are applicable and indicated as treatment options
Pharmacy technician learning objectives
- Identify the pharmacological treatment options for pediatric pulmonary hypertension
- Recognize the brand and generic names of the pharmacological options for the treatment of pediatric pulmonary hypertension
Additional Information
Attachment | Size |
---|---|
![]() | 157.72 KB |
![]() | 124.98 KB |

Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CEU – Attendance